Multikinase inhibitors (MKIs): Information for patients with advanced differentiated thyroid cancer

If your doctor has told you that you may be resistant to radioactive iodine treatment, you may want to know what this means for you and what treatment options may be available for you.

In the last few years, targeted biological therapies have emerged as promising new treatments for different types of cancer. These therapies aim to block cancer cells by interfering with specific molecules in these cells that make them grow and divide, while doing little damage to normal cells. Traditional chemotherapy aims to stop the growth of cancer cells by blocking all rapidly dividing cells, thus causing more damage to normal cells.

Multikinase inhibitors (MKIs) are a type of targeted therapy. They inhibit (block) chemical messengers called tyrosine kinases or multikinases in cancer cells. Blocking these messengers stops the cells from growing and dividing. They are used in the treatment of advanced thyroid cancer as well as other types of cancer such as liver and kidney cancer.

MKI drugs will not cure your cancer, but they may stop the cancer from progressing further for months, even years, and give you a significant symptom free or trouble-free period. However, this needs to be balanced against the possible side effects. Treatment with an MKI is not always appropriate; it will depend on a number of factors including any other medical conditions you may have and how well you feel. Some patients may show no progression for years or have excellent quality of life with no symptoms at all; they might just require regular monitoring with blood tests and scans. In other cases, additional surgery or radiotherapy may be an option before considering an MKI. It is important therefore to start the...
treatment after a multidisciplinary discussion and weighing the options.

Your doctor may also talk to you about any available clinical trials that may be suitable for your situation.

There are several MKIs that have been approved for treating advanced differentiated thyroid cancer and/or advanced metastatic medullary cancer by the Food and Drug Administration (USA) and European Medicines Agency (EMA). These are:

- Sorafenib (Nexavar)
- Lenvatinib (Lenvima)
- Cabozantinib (Cometriq)
- Vandetanib (Caprelsa)

Sorafenib and lenvatinib have been approved for use in treating advanced differentiated thyroid cancer.

Not all MKI drugs are available in every country. Each country has its own regulatory process that a new drug has to go through once it has been FDA/EMA-approved.

There are other MKIs that are going through clinical trials.

If your doctor suggests that you start taking an MKI, don’t hesitate to ask what the treatment involves and what it may involve for you. It is important that you think about the quality of life you want to have and talk with your clinical team about your own preferences.

How to take your MKI medication

All of the available MKI drugs are in the form of tablets that you can take in your own home. It is important to get the advice of your clinical team about how to take your tablets and when. Please also read the manufacturer’s patient information leaflet (PIL). Do not hesitate to ask if there is anything that is not clear to you.

It is important that you inform your doctor about ALL your medications.

Coping with side effects

It is important to discuss the possible side effects with your doctor beforehand and agree a plan on how to manage these. Knowing in advance what side effects might occur and how they can be managed is half the battle.

Not everyone experiences these side effects to the same degree; some people may have very few side effects if at all.

If the side effects become troublesome, talk with your doctor about the alternatives. These might involve changing to another drug, stopping the drug for a while and then restarting (a drug ‘holiday’) or stopping the treatment completely.

Make sure that you have a list of contact telephone numbers or email addresses for your clinical team and that you know who to contact if you are experiencing side effects and you want advice.
treatment after a multidisciplinary dis-
cussion and weighing the options.

Your doctor may also talk to you about
any available clinical trials that may be
suitable for your situation.

There are several MKIs that have been
approved for treating advanced dif-
ferentiated thyroid cancer and/or ad-
vanced metastatic medullary cancer
by the Food and Drug Administration
(USA) and European Medicines Agen-
cy (EMA). These are:

• Sorafenib (Nexavar)
• Lenvatinib (Lenvima)
• Cabozantinib (Cometriq)
• Vandetanib (Caprelsa)

Sorafenib and lenvatinib have been ap-
proved for use in treating advanced dif-
ferentiated thyroid cancer.

Not all MKI drugs are available in ev-
ery country. Each country has its own
regulatory process that a new drug has
go through once it has been FDA/
EMA-approved.

There are other MKIs that are going
through clinical trials.

If your doctor suggests that you start
taking an MKI, don't hesitate to ask
what the treatment involves and what it
may involve for you. It is important that
you think about the quality of life you
want to have and talk with your clinical
team about your own preferences.

How to take your MKI medication
All of the available MKI drugs are in the
form of tablets that you can take in your
own home. It is important to get the ad-
vice of your clinical team about how to
take your tablets and when. Please also
read the manufacturer's patient informa-
tion leaflet (PIL). Do not hesitate to ask if
there is anything that is not clear to you.

It is important that you inform your
doctor about ALL your medications.

Coping with side effects
It is important to discuss the possible
side effects with your doctor before-
hand and agree a plan on how to man-
age these. Knowing in advance what
side effects might occur and how they
can be managed is half the battle.

Not everyone experiences these side ef-
fects to the same degree; some people
may have very few side effects if at all.
If the side effects become troublesome,
talk with your doctor about the alterna-
tives. These might involve changing to
another drug, stopping the drug for a while
and then restarting (a drug 'holiday') or
stopping the treatment completely.

Make sure that you have a list of contact
telephone numbers or email addresses
for your clinical team and that you know
who to contact if you are experiencing
side effects and you want advice.

<table>
<thead>
<tr>
<th>Side effect</th>
<th>What can be done</th>
</tr>
</thead>
<tbody>
<tr>
<td>Constipation</td>
<td>Your doctor can prescribe laxatives. Constipation can also be helped by eating plenty of fibre (grains, fruits and vegetables), drinking plenty of water and taking gentle exercise.</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>If you have loose bowel movements, contact your clinical team as it is important to prevent dehydration and loss of electrolytes. They can prescribe medication for you. It is important to drink plenty of water.</td>
</tr>
<tr>
<td>Fatigue</td>
<td>If you feel tired, it is important to try and pace yourself. Get as much rest as you need and try to balance this with gentle exercise such as walking, bicycling or swimming. Your bloods and thyroid function tests also need checking regularly.</td>
</tr>
<tr>
<td>Hair thinning</td>
<td>Some temporary hair loss may occur but it is unlikely you will lose all your hair. Contact your clinical team if you think it is getting worse.</td>
</tr>
<tr>
<td>Hand/foot skin reaction</td>
<td>The palms of your hands and the soles of your feet may become red, dry or itchy. It is important that you alert your clinical team as soon as you notice symptoms. They can advise you about creams and lotions that may help and prevent the problem from getting worse. If you develop severe symptoms or blisters, talk to your doctor immediately. Benign skin conditions and skin cancers can also develop rarely.</td>
</tr>
<tr>
<td>Hoarseness of voice</td>
<td>Some people may develop a hoarse voice.</td>
</tr>
</tbody>
</table>
Multikinase inhibitors (MKIs): Information for patients with advanced differentiated thyroid cancer

In the last few years, targeted biological therapies have emerged as promising new treatments for different types of cancer. These therapies aim to block cancer cells by interfering with specific molecules in these cells that make them grow and divide, while doing little damage to normal cells. Traditional chemotherapy aims to stop the growth of cancer cells by blocking all rapidly dividing cells, thus causing more damage to normal cells.

Multikinase inhibitors (MKIs) are a type of targeted therapy. They inhibit (block) chemical messengers called tyrosine kinases or multikinases in cancer cells. Blocking these messengers stops the cells from growing and dividing. They are used in the treatment of advanced thyroid cancer as well as other types of cancer such as liver and kidney cancer.

MKI drugs will not cure your cancer, but they may stop the cancer from progressing further for months, even years, and give you a significant symptom free or trouble-free period. However, this needs to be balanced against the possible side effects. Treatment with an MKI is not always appropriate; it will depend on a number of factors including any other medical conditions you may have and how well you feel. Some patients may show no progression for years or have excellent quality of life with no symptoms at all; they might just require regular monitoring with blood tests and scans. In other cases, additional surgery or radiotherapy may be an option before considering an MKI. It is important therefore to start the

If your doctor has told you that you may be resistant to radioactive iodine treatment, you may want to know what this means for you and what treatment options may be available for you.

Copies of the patient leaflets are available in English, French, German and Spanish on request from:
Thyroid Cancer Alliance
PO Box 359 | Diss, Norfolk
IP22 2NX
United Kingdom

Leaflets are also available online:
www.thyroidcanceralliance.org
www.thyroidcancerpatientinfo.org

Voluntary donations to help with printing and postage are welcome. Please contact info@thyroidcanceralliance.org

© Thyroid Cancer Alliance May 2016
This information is prepared by the Thyroid Cancer Alliance, which is an international network of national thyroid cancer patient support organisations working together to provide support and information to those affected by the disease throughout the world. It is an outcome of a patient-led workshop on ‘TKIs and what this means to patients,’ which was held in Paris, October 2014. Please note, this information does not replace the information provided by your doctor. Always ask your clinical team if there is anything that is not clear to you.
This workshop and the follow-up meeting in Orlando, FL in October 2015 were supported by Bayer.

www.thyroidcanceralliance.org